The only previous prospective investigation of cancer risk in carriers observed that, among 16 carriers of t(11;22)(q23:q11), one of the two subjects who developed cancer during follow‐up had breast cancer, but this did not reach statistical significance (SIR = 2.63, 95% CI: 0.30–9.50). 8 It is unclear why the relative risk increases were greater for in situ than invasive breast cancer.
← all excerpts
Mortality and cancer incidence in carriers of constitutional t(11;22)(q23;q11) translocations: A prospective study.
1
—
—